Compare Shanghai Pharmaceuticals Holding Co., Ltd. with Similar Stocks
Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 0.65% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Dec 19
3
With ROE of 9.56%, it has a Very Expensive valuation with a 0.14 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
HKD 10,781 Million ()
1.00
NA
0.00%
0.17
8.93%
0.13
Revenue and Profits:
Net Sales:
75,147 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,083 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.2%
0%
3.2%
6 Months
-1.89%
0%
-1.89%
1 Year
5.66%
0%
5.66%
2 Years
4.01%
0%
4.01%
3 Years
-18.44%
0%
-18.44%
4 Years
-19.87%
0%
-19.87%
5 Years
-22.37%
0%
-22.37%
Shanghai Pharmaceuticals Holding Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.97%
EBIT Growth (5y)
0.65%
EBIT to Interest (avg)
4.71
Debt to EBITDA (avg)
1.73
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
2.17
Tax Ratio
29.24%
Dividend Payout Ratio
30.34%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
10.03%
ROE (avg)
10.26%
Valuation key factors
Factor
Value
P/E Ratio
1
Industry P/E
Price to Book Value
0.14
EV to EBIT
4.06
EV to EBITDA
2.95
EV to Capital Employed
0.31
EV to Sales
0.11
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
7.76%
ROE (Latest)
9.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Dec 2022
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
75,147.10
80,291.20
-6.41%
Operating Profit (PBDIT) excl Other Income
2,782.10
2,473.20
12.49%
Interest
444.50
429.50
3.49%
Exceptional Items
240.20
40.90
487.29%
Consolidate Net Profit
1,083.30
1,083.30
Operating Profit Margin (Excl OI)
25.40%
20.00%
0.54%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -6.41% vs 5.06% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 0.00% vs -70.07% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
306,982.70
297,900.20
3.05%
Operating Profit (PBDIT) excl Other Income
12,136.80
12,260.00
-1.00%
Interest
1,988.40
2,150.30
-7.53%
Exceptional Items
-793.30
-348.50
-127.63%
Consolidate Net Profit
7,563.20
6,364.40
18.84%
Operating Profit Margin (Excl OI)
28.80%
31.70%
-0.29%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.05% vs 3.87% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 18.84% vs 11.48% in Dec 2024
About Shanghai Pharmaceuticals Holding Co., Ltd. 
Shanghai Pharmaceuticals Holding Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






